No Data
No Data
Bausch + Lomb (NYSE:BLCO) Has A Somewhat Strained Balance Sheet
Why Is Clearside Biomedical Stock Gaining Today?
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $23
Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $23
Bausch + Lomb INFUSE for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
Benjamin’s : New CEO